ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, K. C.
Right arrow Articles by Leung, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, K. C.
Right arrow Articles by Leung, C. C.
Eur Respir J 2008; 31:906-907
Copyright ©ERS Journals Ltd 2008

Meta-analysis may not be practicable for guiding antibiotic therapy

K. C. Chang and C. C. Leung

Tuberculosis and Chest Service, Centre for Health Protection, Department of Health, Hong Kong, China.

To the Editors:

We read with interest a meta-analysis by Siempos et al. 1 that showed that macrolides, quinolones and amoxicillin/clavulanate might be considered equivalent for treating acute bacterial exacerbation of chronic bronchitis. Despite meticulous adherence to the methodology of meta-analysis and a comprehensive discussion of the major limitations of their study, the investigators might have used an inappropriate tool for addressing a common clinical problem.

Although meta-analysis has been placed at the pinnacle of the hierarchy of clinical evidence 2, caution is required for clinical scenarios in which targeted pathogens and their drug sensitivity patterns may vary with geographical location and time. One such scenario is the antibiotic treatment of lower respiratory tract infection, including pneumonia and chronic bronchitis, for which the clinical decision is often empirical and heavily dependent upon timely and relevant epidemiological data, as well as the patient’s clinical characteristics 3, 4. Fundamental differences in these major factors that existed between the study populations from different locations and periods would have rendered it meaningless to find summary estimates with meta-analysis.

The only valid finding may be their conclusion about the significantly higher association between adverse effects and amoxicillin/clavulanate in comparison with quinolones, since adverse events may be subject to less variation due to time, place and person. That notwithstanding, the choice of antibiotic for empirical treatment must also take into account the inherent diagnostic uncertainty and long-term implications for resistance profiles. In this regard, fluoroquinones have been incriminated in causing a delay in the diagnosis of tuberculosis 5. Thus, fluoroquinolones have been reserved for use only in certain settings in some tuberculosis-endemic populations.

Statement of interest

None declared.

REFERENCES

  1. Siempos II, Dimopoulos G, Korbila IP, Manta K, Falagas ME. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007;29:1127–1137.[Abstract/Free Full Text]
  2. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. Users’ guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA 1995;274:1800–1804.[Abstract/Free Full Text]
  3. Adams SG, Anzueto A. Antibiotic therapy in acute exacerbations of chronic bronchitis. Semin Respir Infect 2000;15:234–247.[Medline] [Order article via Infotrieve]
  4. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44: Suppl. 2 S27–S72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  5. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002;34:1607–1612.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, K. C.
Right arrow Articles by Leung, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, K. C.
Right arrow Articles by Leung, C. C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS